QQ客服 官方微博 反馈留言

	Evacetrapib reduces pre beta-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes
	Chen, Xueying; Jiang, Xian-Cheng; Ge, Junbo; Chen, Haozhu; Chen, Yunqin; Dong, Jibin; Zhang, Xiaojin; Wang, Li
刊名	ATHEROSCLEROSIS
	2019
卷号	285
关键词	CETP inhibitor HDL-cholesterol HDL subclasses Pre beta-1 HDL Pre beta-1 HDL measurement Atherosclerotic cardiovascular disease or diabetes
ISSN号	0021-9150
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3594886
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Chen, Xueying,Jiang, Xian-Cheng,Ge, Junbo,et al. Evacetrapib reduces pre beta-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes[J]. ATHEROSCLEROSIS,2019,285.
APA	Chen, Xueying.,Jiang, Xian-Cheng.,Ge, Junbo.,Chen, Haozhu.,Chen, Yunqin.,...&Wang, Li.(2019).Evacetrapib reduces pre beta-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes.ATHEROSCLEROSIS,285.
MLA	Chen, Xueying,et al."Evacetrapib reduces pre beta-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes".ATHEROSCLEROSIS 285(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。